# Pain Relief After PrimaryTKA

> **NCT05751421** · PHASE3 · UNKNOWN · sponsor: **Rothman Institute Orthopaedics** · enrollment: 60 (estimated)

## Conditions studied

- Pain, Postoperative

## Interventions

- **DRUG:** Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution
- **DRUG:** Bupivacaine HCl 0.5% Injectable Solution
- **PROCEDURE:** primary total knee replacement

## Key facts

- **NCT ID:** NCT05751421
- **Lead sponsor:** Rothman Institute Orthopaedics
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-28
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-02-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05751421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05751421, "Pain Relief After PrimaryTKA". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05751421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*